T3B CABG SURGERY FORM: T3 FORM 26 (Rev. 2)

PURPOSE: To collect data from the coronary bypass operation regarding the number of vessels bypassed, type of conduit used to bypass stenosis, and to identify any major events associated with the procedure.

PERSONS RESPONSIBLE: Certified Research Coordinator.

SOURCES OF INFORMATION: Medical record, post-operative report.

TIME OF DATA COLLECTION: At the time of the operation and during the subsequent 24 hours.

GENERAL INSTRUCTIONS: This form is to be completed each time the patient undergoes a coronary bypass operation.

PART I: IDENTIFICATION

- 1. NAME CODE: As previously defined for the patient.
- 2. DATE OF SURGERY: Self-explanatory.

PART II: PROCEDURE NOTES

- 3. WHEN WAS THIS CABG PERFORMED? Record the timing of the CABG relative to study treatment initiation.
- 4. WHY WAS CABG PERFORMED? Record whether the CABG was done because patient was randomized to the invasive strategy, or a patient assigned to conservative strategy reached a defined study end point, or because of another reason not mandated by the protocol.
- 5. IF CABG WAS PERFORMED IN A PATIENT RANDOMIZED TO THE CONSERVATIVE STRATEGY OR THE CABG WAS "NON-PROTOCOL." Record all reasons for CABG. Items A through G are considered to be protocol defined end points and require documentation using event forms. Items H through K are not considered to be protocol defined end points, and this CABG will be considered a major protocol violation if CABG is performed within the six weeks following study treatment and none of Items A through G is checked.

6. PRIORITY OF CABG:

Emergency: Patient is undergoing CABG on an emergent basis. The patient is clinically unstable, and his/her condition requires immediate revascularization. (CABG must occur within 24 hours of the onset of the event precipitating the CABG requirement.)

Urgent: Patient is undergoing CABG on an urgent basis. The patient may be unstable, have disease that warrants revascularization within 7 days of the precipitating event, or patient is stable but has suffered a complication or event within the past 14 days that substantially increases the risk of an adverse event (e.g., myocardial infarction) if revascularization is not undertaken.

Elective: Patient is undergoing CABG on an elective basis. At the time of revascularization, the patient is clinically stable (Heart Failure Classification < 4), and his/her overall medical condition does not necessitate immediate revascularization.

7. ANGINAL STATUS AT TIME OF CABG:

Stable: Patient is experiencing a pattern of angina that is predictably brought on by the activities in which the

patient engages. The frequency and severity of anginal episodes do not vary to a significant degree from day to day.

Unstable: A pattern of angina that is distinctly changing in severity and frequency in comparison to a previous pattern. The chest discomfort of unstable angina, while similar in quality to stable angina, may be more intense and persist for longer periods of time. Specific categories of unstable angina are: accelerating angina, recurrence of angina within 14 days after infarction, angina lasting more than 20 minutes, angina associated with transient ECG changes, and angina at rest.

Acute event: The patient is currently hospitalized for an MI or has sustained an abrupt closure following attempted PTCA.

- 8. THERAPY PRE-PROCEDURE: Record all therapies administered to the patient within the 48 hours preceding the surgery.
- 9. ARTERIES GRAFTED: Record the vessel(s) grafted and the type of conduit used (A-D as listed in the box).
- 10. COMPLETE REVASCULARIZATION: Check "yes" if all major coronary segments with ≥ 50% luminal diameter narrowing supplying viable myocardium are bypassed. Major coronary segments include all segments listed in the coronary artery diagram (Exhibit 1) that are 1.5 millimeters in diameter.

PART III: MAJOR EVENTS

- 11. MAJOR EVENTS DURING OR WITHIN THE 24 HOURS AFTER CABG: Check "yes" if the patient experienced any of the listed events, either in the operating room or within 24 hours after the surgery.
 - A. Death: Check "yes" if death occurred within 24 hours after surgery. Submit Death Notification Form 15 and Cause of Death Form 16 if death has occurred.
 - B. Non-fatal cardiac arrest: A cardiac arrest that requires CPR or countershock.
 - C. Suspected non-fatal MI: Check "yes" if there is a reason to suspect the occurrence of myocardial infarction, defined as an episode of ischemic pain lasting > 20 minutes in duration, abnormal rise in CK to > 2 times upper limit of normal, or presence of positive CK-MB above the upper limit of normal, or the development of new Q-waves. A Myocardial Infarction Event Form 23 should be completed and submitted if this is checked "yes."

- Congestive heart failure (isolated): Isolated episode of D. congestive heart failure documented by chest x-ray or treatment with diuretics. CHF is a difficult diagnosis. Verification by a physician statement in the medical record is required. In general, CHF is clinically manifest by one or more features including: dyspnea on exertion (DOE--shortness of breath on exertion), bilateral pedal edema, fatigue, orthopnea (sleeping on two or more pillows to facilitate breathing), paroxysmal nocturnal dyspnea (shortness of breath that awakens the patient from sleep). Other findings supporting the clinical manifestations include but are not restricted to: presence of S³ gallup by auscultation, elevated venous jugular pressure > 8 cm H_20 by physical exam, or radiographic evidence of pulmonary congestion.
- E. Pulmonary edema (cardiac): Acute profound left sided congestive heart failure resulting in the accumulation of intra-bronchial and alveolar fluid, reflected by pulmonary rales, a characteristic "bat-wing" appearance on the chest radiograph, and almost always associated with marked dyspnea and hypoxia. If hemodynamic measurements are performed, they will invariably show elevation of the pulmonary capillary wedge pressure above 25 mm Hg.
- F. Cardiogenic shock: Shock defined as a systolic blood pressure < 80 mm Hg which either persists for more than one hour or requires specific treatment for at least one hour. In general, shock is associated with a low urine output, decreased mental acuity or coma, and compensatory vasoconstriction (decreased blood vessel caliper). Hypotension (very low blood pressure) without these associated manifestations of low cardiac output will not be considered as shock.
- G. Cardiac tamponade: The appearance of the following three manifestations are typical of cardiac tamponade from intra-pericardial hemorrhage due to penetrating heart wounds, aortic dissections, and intra-pericardial rupture of an aorta, or cardiac aneurysm: decline in systemic arterial pressure, elevation of systemic venous pressure, and a small, quiet heart.
- H. Arterial embolus of extremity or loss of pulse requiring treatment: Arterial embolus is the acute occlusion of a main or distal arterial trunk supply in a limb, due to formation and distal migration of thrombotic or atherosclerotic material, associated with decreased or loss of limb perfusion, and treated by surgical embolectomy or local thrombolytic therapy. Permanent loss of pulse is the lack of detectable distal arterial pulsations (by pulsation or Doppler examination) which had previously been observable prior to instrumentation of a more proximal arterial branch. Loss of pulse may

or may not be associated with ischemia of the affected limb.

- I. Arterial dissection requiring repair: A tearing of an arterial wall which requires surgical repair.
- J. TIA -- transient ischemic attack: A partial, focal, neurologic deficit which is transient in nature and completely clears within 24 hours after its onset.
- K. Stroke: A focal neurologic deficit which appears and is still at least partially evident more than 24 hours after its onset. Submit Severe Neurologic Event Form 27 if this event has occurred.
- L. Coma: Profound depression in the level of consciousness reflected by loss of contact with the environment and loss of spontaneous movement. Brain stem activity (respiration and response to deep pain) may or may not be preserved. Submit Severe Neurologic Event Form 27 if this event has occurred.
- M. Hypersensitivity reaction: Allergic reaction to iodine containing radiographic contrast media or protamine, marked by the development of urticaria, wheezing, prolonged hypotension, or laryngospasm.
- Respiratory failure: Inability of the patient to maintain N. adequate gas exchange during spontaneous ventilation, even with the assistance of supplemental oxygen. This may be reflected either by marked hypoxia (PO₂ < 50 TORR) or respiratory acidosis with PCO₂ > 45 TORR and pH < 7.30. Respiratory failure meeting the above criteria would usually require endotracheal intubation or tracheostomy, and mechanical ventilatory assistance. In the setting where a patient is receiving mechanical ventilatory assistance following surgery, respiratory failure shall be inability to wean the patient from mechanical ventilation within 48 hours of completion of the surgical procedure.
- O. Pulmonary embolus: Occlusion (partial or complete) of one or more of the pulmonary artery branches with thrombus dislodged from the systemic venous circulation. Newly occurring acute events (e.g., within 24 hours of surgery) are often (but not always) characterized by chest pain and decreases in arterial oxygenation; increased pulmonary artery pressure and even frank hemodynamic collapse may occur. The diagnosis must be supported by a "high probability" (multiple mismatched defects) lung scan and/or a confirmatory (and more definitive) pulmonary angiogram.

- P. Renal failure requiring dialysis: Deteriorating renal function requiring dialysis.
- Q. **Re-operation for bleeding:** Re-operation to remedy bleeding post-surgery.
- R. Wound dehiscence: The splitting or bursting open of a procedural wound.
- S. Mediastinitis: Chart documented inflammation of mediastinum following surgery.
- T. Other Events: Include other major events occurring during or within 24 hours after surgery.
- 12. CONDITION OF PATIENT LEAVING OPERATING ROOM: Enter condition of patient when leaving operating room according to the following criteria:

Stable: Patient is stable clinically and hemodynamically, and is receiving no more than one inotropic agent or one vasopressor.

Unstable: Patient is clinically unstable, that is, experiencing angina at rest, or is hemodynamically unstable and requires more than one inotropic agent or vasopressor, intra-aortic balloon pump, or ventricular assist device (VAD).

DECEASED: Self-explanatory.

PART IV: ADMINISTRATIVE MATTERS

Self-explanatory.



THROMBOLYSIS IN MYOCARDIAL ISCHEMIA

T3 Form 26 Rev. 2 06/11/90 Page 1 of 6

CABG SURGERY FORM 26

Complete this form each time the patient has CABG.

Clínic No.			-				
ID No.			-				
Form Type	В	В				 	

PART I: IDENTIFICATION

1.	Patient's NAME CODE:	 <u> </u>		
0				fm26day
۷.	Date of surgery:		Day	Year

PART II: PROCEDURE NOTES

3.	When was this CABG performed?	cabgtimb
	Less than 18 hours after study treatment initiation	····· (1)
	18 to 48 hours after study treatment initiation	· (₂)
	Greater than 48 hours after study treatment initiation but before or at six-week follow-up visit	····· (₃)
	After six-week follow-up visit	(4)
4.	Why was this CABG performed?	cabgtype
	Protocol (Invasive Strategy)	· (1)*

Protocol (Conservative Strategy patient with study end point) ($_2$)
Non-protocol)

*If Protocol (Invasive Strategy), skip to Item 6, page 3.

ID No.		-	{ .	ł.	
				1	

T3 Form 26 Rev. 2 06/11/90 Page 2 of 6

- 5. If <u>Protocol CABG (Conservative Strategy Patient)</u> or <u>non-protocol CABG for patients</u> in <u>either strategy</u>, check all the reasons for revascularization which were fulfilled at the time of performance of this surgery:
 - A. MI after study drug treatment ------ micabg (1)*
 - B. Ischemic pain <u>at rest</u> with ECG changes meeting study criteria (1)*

t

(Check all that apply.)

C. Notification from Holter Core Lab of abnormal Holter Test $(1)^*$ D. Positive Thallium Imaging Test: a) abnormal lung uptake and ≥ 1 region with reversible hypoperfusion; or b) ≥ 2 regions tptcabg with reversible hypoperfusion -----Positive ETT Test: a) ischemic pain prior to completion of Ε. Stage II; or b) $\geq 2 \text{ mm}$ ST elevation/depression with or without ettcabg symptoms; or c) \geq 10 mm Hg reduction in SBP compared to F. Post-discharge Canadian Cardiovascular Society Class III or CCSCCabg IV angina confirmed by ETT (1)* rangcabg G. Rest angina requiring re-hospitalization ------ (1)* anatcabg H. Coronary anatomy (1)pmdcabq I. Decision of personal physician ----- (1)** pvcabdg othcabq K. Other ------ (1)** Specify:

*Submit appropriate event, ECGs and test forms to Core Laboratories and the DCC. **<u>PROTOCOL VIOLATION</u> if surgery performed within six weeks of study treatment and none of Items A-G is checked.

ID No.			-			
Form Type	B	В				

T3 Form 26 Rev. 2 06/11/90 Page 3 of 6

6. Indicate surgical priority:

,

- -	cabgprio
Emergency	$\begin{pmatrix} 1 \\ 1 \end{pmatrix}$
Elective	(2)

7. Patient's anginal status at time of surgery:

Stable	cabgang
Stable	····· (₁)
Unstable	()
Acute event	(2)
Acute event	(3)

8. Were any of the following therapies administered during the 48 hours prior to procedure? (Answer each item.)

A. B. C. D.	Heparin	rcubera	Yes (1) (1) (1) (1) (1)	<u>No</u> (2) (2) (2) (2) (2)	$\binom{3}{3}$
E. F. G. H.	Antiplatelet agents other than ASA or pergaptine		(1) (1) (1) (1) (1)	(2) (2) (2) (2) (2)	$\binom{3}{3}$
I. J. K. L.	Lipid-lowering agent	rcharat.	$\binom{1}{1}$	$\binom{2}{2}$	$\binom{3}{3}$
M. N. O. P.	Digitalis or derivative	rcoinot	()	$\binom{2}{2}$	(3) (3) (3)
Q. R. S.	IV nitroglycerin	rcbivni rcbthrm rcbiabp	$\binom{1}{1}$	(2) (2) (2) (2)	

ID No.			-				
Form Type	В	В					

T3 Form 26 Rev. 2 06/11/90 Page 4 of 6

Conduit codes for use in Question 9.

- A. Saphenous vein(s).
- B. Left internal mammary artery.C. Right internal mammary artery.
- D. Other.
- 9. Arteries grafted:

ALCE.	ties glatted.		Yes	No	<u>Conduít</u>
A.	LAD	ladcabg	(1)	(2)	<u>Used</u> ladcabgc
В.	lst diagonal	<u>d1cabg</u>	(1)	(2)	<u>d1</u> cabgc
С.	2nd diagonal	d2cabg	(1)	(2)	<u>d</u> 2cabgc
D.	Circumflex		(₁)	(₂)	<u>cf</u> cabgc
Ε.	lst obtuse marginal	omlcabg	(1)	(₂)	omlcabgc
F.	2nd obtuse marginal		(1)	(₂)	om2cabgc
G.	3rd obtuse marginal		(1)	(₂)	om3cabgc
H.	Ramus intermedius		(1)	(2)	ricabgc
I.	RCA	rcacabg	(1)	(2)	rcacabgc
J.	PDA	pdacabg	(₁)	(₂)	pdacabgc

				revscabg			
10.	Was re	vascularization	complete?		(1)	(₂)	(3)
					Yes	No	U nkno wn

ID No.			-				
Form Type	В	B					

T3 Form 26 Rev. 2 06/11/90 Page 5 of 6

PART III: MAJOR EVENTS

Answ	ver each item:		Did not	Occurred	Occurred within
Α.	Deathdth	124	<u> </u>	<u>in O.R.</u>	24 Hours
			(1)	(₂)*	(3)*
	NON-fatal cardiac arrest	oqca			
В.	Suspected non-fatal MI	oqmi	$\begin{pmatrix} 1 \end{pmatrix}$	$\binom{2}{2}$	$\begin{pmatrix} 3 \end{pmatrix}$
C.	Congestive heart failure (isolated) Cal	oachf	$\begin{pmatrix} 1 \end{pmatrix}$	(₂)**	(3)**
D.	Pulmonary edema (cardiac)	ogedem	$\begin{pmatrix} 1 \end{pmatrix}$	(₂)	$\begin{pmatrix} 3 \end{pmatrix}$
Ε.	Cardiogenic shock	ashck	$\begin{pmatrix} 1 \end{pmatrix}$	(₂)	$\begin{pmatrix} 3 \end{pmatrix}$
F. G.	Cardiac tamponade	ogtamp	$\begin{pmatrix} 1 \\ \end{pmatrix}$	$\binom{2}{2}$	$\begin{pmatrix} 3 \end{pmatrix}$
	Artorial ambalua of automity or		(1)	(₂)	(3)
Н.	Arterial embolus of extremity <u>or</u> loss of pulse requiring treatment <u>cal</u>	ogembo			
Ŧ	loss of pulse requiring treatment	odiss	$\begin{pmatrix} 1 \end{pmatrix}$	(₂)	(3)
I.	Arterial dissection requiring repair - Cal		(₁)	(₂)	(3)
NEUDO	DLOGIC EVENTS				
J.	Ca.	ogtia			
J. К.	Stroke cat	ogstrk	$\begin{pmatrix} 1 \end{pmatrix}$	$\binom{2}{2}$	
K. L.	Coma cak	oqcoma	$\begin{pmatrix} 1 \end{pmatrix}$	(₂)***	
ц.	Coma		(1)	(₂)***	(3)***
ALLE	RGIC EVENT				
M.	RGIC EVENT cal Hypersensitivity reaction	ogairg	(₁)	(₂)	(3)
PULMO N.	DNARY EVENTS Respiratory failure (include ARDS & non-ca				
	edema)cal	ogards.	(1)	(₂)	(3)
Ο.	Pulmonary emboluscal	ogplem	$\begin{pmatrix} 1 \\ 1 \end{pmatrix}$	(2)	$\begin{pmatrix} 3 \\ 3 \end{pmatrix}$
				. 2	
RENAI	LEVENT				
Ρ.	Renal failure requiring dialysis cal	pgalal	(1)	(₂)	(3)
PROCI	EDURAL EVENTS	pareop			
Q.	Re-operation for bleeding cab	gund	(1)	(₂)	(3)
R.	Wound dehiscence		(1)	(₂)	(3)
S.	Mediastinitis or wound infection Cak	<u>diur</u>	(1)	(₂)	(3)
	R EVENTS (Do not include study end point or	ischemi		, ·	,
Τ.	Other eventscal	youev.	(1)	(₂)	(3)
	Specify:	·	_		
*Suhm	it Death Notification Form 15 and Cause of 1	Death Fo	rm 16	×	
	it Myocardial Infarction Event Form 23.	Jeall FO	1111 10.		
	it Severe Neurologic Event Form 27.				
Subm.	to concrete montoregre svent rorm 2/.				

ID No.			-				
Form Type	В	В				L	f

T3 Form 26 Rev. 2 06/11/90 Page 6 of 6

Unstable ($_2$)

Deceased ($_3$)

Ŧ

Submit Death Notification Form 15 to DCC within 72 hours and Cause of Death Form 16 within 14 days.

PART IV: ADMINISTRATIVE MATTERS

13.	Surgeon:	
	Name:	T3 Staff No.:
14.	Research Coordinator:	
	Signature:	T3 Staff No.:
15.	Date form completed:	Month Day Year

ID No.			-]
Form Type	В	В					-

T3 Form 26: Variables from earlier revisions

- HR24CABG Revision 1 Item 3A When was this CABG performed? Within 24 hours of study enrollment 1=Yes
- BETWCABG Revision 1 Item 3B When was this CABG performed? Between 24 hours after enrollment and 6-week follow-up 1=Yes
- AFTCABG Revision 1 Item 3C When was this CABG performed? After 6-week follow-up 1=Yes
- CABGTUBE Revision 1 Item 100 Chest tube not removed ≥ 5 days post-CABG 1=Did not Occur 2=Occurred in OR 3=Occurred within 24 hours

The	CONTENTS	Procedure
-----	-----------------	-----------

Data Set Name:	WORK.FORM26	Observations:	449
Member Type:	DATA	Variables:	88
Engine:	V8	Indexes:	0
Created:	8:25 Tuesday, February 10, 2004	Observation Length:	336
Last Modified:	8:25 Tuesday, February 10, 2004	Deleted Observations:	0
Protection:		Compressed:	NO
Data Set Type:		Sorted:	NO
Label:			

		Alphabe	etic List of	Variables a	nd Attributes
#	Variable	Туре	Len	Pos	Label
5	AFTCABG	Num	4	32	f26q3C: CABG after 6wk follow-up
18	ANATCABG	Num	4	84	f26q5H: Coronary anatomy
4	BETWCABG	Num	4	28	f26q3B: CABG between 24 hrs and 6 wks
77	CABGALRG	Num	4	280	f26q11M: Hypersensitivity
23	CABGANG	Num	4	104	f26q7: Anginal status at surgery
78	CABGARDS	Num	4	284	f26q11N: Respiratory failure
66	CABGCA	Num	4	236	f26q11B: Non-fatal cardiac arrest
68	CABGCHF	Num	4	244	f26q11D: Congestive heart failure
76	CABGCOMA	Num	4	276	f26q11L: Coma
81	CABGDIAL	Num	4	296	f26q11P: Renal failure
73	CABGDISS	Num	4	264	f26q11I: Arterial dissection
69	CABGEDEM	Num	4	248	f26q11E: Pulmonary edema
72	CABGEMBO	Num	4	260	f26q11H: Arterial embolus
64	CABGEVNT	Num	4	228	f26q11: Any major events
84	CABGINF	Num	4	308	f26q11S: Mediastinitis
67	CABGMI	Num	4	240	f26q11C: Suspected MI
85	CABGOTEV	Num	4	312	f26q11T: Other events
79	CABGPLEM	Num	4	288	f26q11O: Pulmonary embolus
22	CABGPRIO	Num	4	100	f26q6: Surgical priority
82	CABGREOP	Num	4	300	f26q11Q: Re-operation for bleeding
70	CABGSHCK	Num	4	252	f26q11F: Cardiogenic shock
86	CABGSTAT	Num	4	316	f26q12: Condition leaving O.R.

(10FEB04--08:25)

The CONTENTS Procedure

		Alphabe	etic List of	Variables a	nd Attributes
#	Variable	Туре	Len	Pos	Label
75	CABGSTRK	Num	4	272	f26q11K: Stroke
71	CABGTAMP	Num	4	256	f26q11G: Cardiac tamponade
74	CABGTIA	Num	4	268	f26q11J: TIA
6	CABGTIMB	Num	4	36	f26q3: When CABG performed
80	CABGTUBE	Num	4	292	f26q10O: Chest tube not removed > 5 days
7	CABGTYPE	Num	4	40	f26q4: Why CABG performed
83	CABGWND	Num	4	304	f26q11R: Wound dehiscence
16	CCSCCABG	Num	4	76	f26q5F: Post-discharge class III or IV
49	CFCABG	Num	4	196	f26q9D: Circumflex grafted
50	CFCABGC	Char	1	327	f26q9D: Circumflex conduit
45	D1CABG	Num	4	188	f26q9B: 1st diagonal grafted
46	D1CABGC	Char	1	325	f26q9B: 1st diagonal conduit
47	D2CABG	Num	4	192	f26q9C: 2nd diagonal grafted
48	D2CABGC	Char	1	326	f26q9C: 2nd diagonal conduit
65	DTH24	Num	4	232	f26q11A: Death within 24 hrs
15	ETTCABG	Num	4	72	f26q5E: Positive ETT
88	FM26DAY	Num	8	16	f26q2: Days to surgery
2	FMTYP	Char	4	320	Form Type
13	HOLTCABG	Num	4	64	f26q5C: Abnormal holter test
3	HR24CABG	Num	4	24	f26q3A: CABG within 24 hrs of enrollment
10	ISCHT1	Num	4	52	f26q5B1: Single episode ischemic pain
11	ISCHT2	Num	4	56	f26q5B2: Ischemic pain 20 min
12	ISCHT3	Num	4	60	f26q5B3: Ischemic pain multiple episodes
43	LADCABG	Num	4	184	f26q9A: LAD grafted
44	LADCABGC	Char	1	324	f26q9A: LAD conduit
8	MICABG	Num	4	44	f26q5A: MI after treatment
87	NEWID	Num	8	8	Patient Identification
51	OM1CABG	Num	4	200	f26q9E: 1st obtuse marginal grafted
52	OM1CABGC	Char	1	328	f26q9E: 1st obtuse marginal conduit
53	OM2CABG	Num	4	204	f26q9F: 2nd obtuse marginal grafted
54	OM2CABGC	Char	1	329	f26q9F: 2nd obtuse marginal conduit

(10FEB04--08:25)

The CONTENTS Procedure

		Alphabe	tic List of	Variables a	and Attributes
#	Variable	Туре	Len	Pos	Label
55	OM3CABG	Num	4	208	f26q9G: 3rd obtuse marginal grafted
56	OM3CABGC	Char	1	330	f26q9G: 3rd obtuse marginal conduit
21	OTHCABG	Num	4	96	f26q5K: Other reason
9	PAINCABG	Num	4	48	f26q5B: Ischemic pain
61	PDACABG	Num	4	220	f26q9J: PDA grafted
62	PDACABGC	Char	1	333	f26q9J: PDA conduit
19	PMDCABG	Num	4	88	f26q5I: Decision of personal physician
34	PRCBACEI	Num	4	148	f26q8K: ACE inhibitor pre CABG
30	PRCBASA	Num	4	132	f26q8G: Aspirin pre CABG
26	PRCBBETA	Num	4	116	f26q8C: Beta-blockers pre CABG
27	PRCBCCB	Num	4	120	f26q8D: Calcium channel blocker pre CABG
31	PRCBCOAG	Num	4	136	f26q8H: Anticoagulant pre CABG
36	PRCBDIGI	Num	4	156	f26q8M: Digitalis pre CABG
35	PRCBDILA	Num	4	152	f26q8L: Vasodilator pre CABG
33	PRCBDIUR	Num	4	144	f26q8J: Diuretic pre CABG
39	PRCBFISH	Num	4	168	f26q8P: Fish oil pre CABG
24	PRCBHEP	Num	4	108	f26q8A: Heparin pre CABG
42	PRCBIABP	Num	4	180	f26q8S: IABP pre CABG
37	PRCBINOT	Num	4	160	f26q8N: Inotropic agent pre CABG
40	PRCBIVNI	Num	4	172	f26q8Q: IV nitroglycerin pre CABG
32	PRCBLIPL	Num	4	140	f26q8I: Lipid-lowering agent pre CABG
25	PRCBNITR	Num	4	112	f26q8B: Nitrates pre CABG
28	PRCBPERS	Num	4	124	f26q8E: Persantine pre CABG
29	PRCBPLAT	Num	4	128	f26q8F: Antiplatlet agents pre CABG
38	PRCBRHYT	Num	4	164	f26q8O: Antiarrhythmic agent pre CABG
41	PRCBTHRM	Num	4	176	f26q8R: Thrombolytic therapy pre CABG
20	PVCABG	Num	4	92	f26q5J: Clinical decision
17	RANGCABG	Num	4	80	f26q5G: Rest Angina requiring re-hosp
59	RCACABG	Num	4	216	f26q9I: RCA grafted
60	RCACABGC	Char	1	332	f26q9I: RCA conduit
1	REV	Num	8	0	Revision

(10FEB04--08:25)

The CONTENTS Procedure

	Alphabetic List of Variables and Attributes								
#	# Variable Type Len Pos Label								
63	REVSCABG	Num	4	224	f26q10: Revascularization complete				
57	RICABG	Num	4	212	f26q9H: Ramus intermedius grafted				
58	RICABGC	Char	1	331	f26q9H: Ramus intermedius conduit				
14	TPTCABG	Num	4	68	f26q5D: Positive thallium imaging test				

T3B form26

Variable	Label	Value	Ν	%	<= 20
REV	Revision	0	9	2.0	*
		1	52	11.6	
		2	388	86.4	
FMTYP	Form Type	BB01	447	99.6	
		BB02	1	0.2	*
		BB03	1	0.2	*
CABGTIMB	f26q3: When CABG performed		61	13.6	
		1	5	1.1	*
		2	29	6.5	
		3	276	61.5	
		4	78	17.4	
HR24CABG	f26q3A: CABG within 24 hrs of enrollment		445	99.1	
		1	4	0.9	*
BETWCABG	f26q3B: CABG between 24 hrs and 6 wks		398	88.6	
		1	51	11.4	
AFTCABG	f26q3C: CABG after 6wk follow-up		443	98.7	
		1	6	1.3	*
CABGTYPE	f26q4: Why CABG performed	1	185	41.2	
		2	180	40.1	
		3	84	18.7	
MICABG	f26q5A: MI after treatment		421	93.8	
		1	28	6.2	
PAINCABG	f26q5B: Ischemic pain		357	79.5	
		1	92	20.5	

T3B form26

Variable	Label	Value	N	%	<= 20
ISCHT1	f26q5B1: Single episode ischemic pain		433	96.4	
		1	16	3.6	*
ISCHT2	f26q5B2: Ischemic pain 20 min		407	90.6	
		1	42	9.4	
ISCUT2	D(sD). Isohamia nain multiple aniso dag		412	02.0	
ISCHT3	f26q5B3: Ischemic pain multiple episodes	1	413 36	92.0 8.0	
		1	50	8.0	
HOLTCABG	f26q5C: Abnormal holter test		432	96.2	
notrendo		1	17	3.8	*
			- ,		
TPTCABG	f26q5D: Positive thallium imaging test		376	83.7	
		1	73	16.3	
ETTCABG	f26q5E: Positive ETT		379	84.4	
		1	70	15.6	
CCSCCABG	f26q5F: Post-discharge class III or IV		445	99.1	
		1	4	0.9	*
DANGGADG			202	05.0	
RANGCABG	f26q5G: Rest Angina requiring re-hosp	1	383 66	85.3 14.7	
		1	00	14./	
ANATCABG	f26q5H: Coronary anatomy		368	82.0	
		. 1	81	18.0	
PMDCABG	f26q5I: Decision of personal physician		409	91.1	
		1	40	8.9	
PVCABG	f26q5J: Clinical decision		435	96.9	
		1	14	3.1	*

T3B form26

Variable	Label	Value	Ν	%	<= 20
OTHCABG	f26q5K: Other reason	•	432	96.2	
		1	17	3.8	*
CABGPRIO	f26q6: Surgical priority	1	64	14.3	
		2	236	52.6	
		3	149	33.2	
CABGANG	f26q7: Anginal status at surgery	1	301	67.0	
		2	129	28.7	
		3	19	4.2	*
PRCBHEP	f26q8A: Heparin pre CABG	1	341	75.9	
		2	101	22.5	
		3	7	1.6	*
PRCBNITR	f26q8B: Nitrates pre CABG	1	320	71.3	
		2	123	27.4	
		3	6	1.3	*
PRCBBETA	f26q8C: Beta-blockers pre CABG	1	342	76.2	
		2	100	22.3	
		3	7	1.6	*
PRCBCCB	f26q8D: Calcium channel blocker pre CABG	1	348	77.5	
		2	94	20.9	
		3	7	1.6	*
PRCBPERS	f26q8E: Persantine pre CABG	1	54	12.0	
		2	388	86.4	
		3	7	1.6	*

T3B form26

PRCBPLAT f26q8F: Antiplatlet agents pre CABG 1 1 0.2 2 441 98.2 3 7 1.6 PRCBASA f26q8G: Aspirin pre CABG 1 229 51.0 2 213 47.4 3 7 1.6 PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 2 440 98.0 3 6 1.3 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2 3 7 1.6	
PRCBASA f26q8G: Aspirin pre CABG 1 229 51.0 PRCBASA f26q8G: Aspirin pre CABG 1 229 51.0 PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2	*
PRCBASA f26q8G: Aspirin pre CABG 1 229 51.0 2 213 47.4 3 7 1.6 PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 2 440 98.0 3 6 1.3 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2	
PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2	*
PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2	
PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 7 1.6 PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 2 440 98.0 3 6 1.3 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2	
PRCBCOAG f26q8H: Anticoagulant pre CABG 1 3 0.7 2 440 98.0 3 6 1.3 PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2	
PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2	*
PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2	
PRCBLIPL f26q8I: Lipid-lowering agent pre CABG 1 37 8.2 2 405 90.2	*
PRCBLIPLf26q8I: Lipid-lowering agent pre CABG1378.2240590.2	
2 405 90.2	*
2 405 90.2	
3 7 1.6	
	*
PRCBDIUR f26q8J: Diuretic pre CABG 1 68 15.1	
2 375 83.5	
3 6 1.3	*
PRCBACEIf26q8K: ACE inhibitor pre CABG1357.8	
2 407 90.6	
3 7 1.6	*
PRCBDILA f26q8L: Vasodilator pre CABG 1 6 1.3	*
2 436 97.1	
3 7 1.6	*
PRCBDIGI f26q8M: Digitalis pre CABG 1 22 4.9	
2 420 93.5	
3 7 1.6	*

T3B form26

PRCBINOT 126q8N: Inotropic agent pre CABG 1 6 1.3 * PRCBRHYT 126q8O: Antiarrhythmic agent pre CABG 1 17 3.8 * PRCBRHYT 126q8O: Antiarrhythmic agent pre CABG 1 17 3.8 * PRCBFISH 126q8P: Fish oil pre CABG 2 443 98.7 * PRCBIVNI 126q8Q: IV nitroglycerin pre CABG 1 160 35.6 1.3 * PRCBTHRM 126q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBTHRM 126q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBTHRM 126q9R: LAD grafted 1 46 10.2 * PRCBIABG 126q9A: LAD grafted 1 48 93.1 * LADCABGC 126q9A: LAD conduit . 32 7.1 * LADCABGC 126q9A: LAD conduit . 32 7.1 * LADCABGC 126q9A: LAD conduit . 32 7.1 * LADCABGC 126q9A: LAD conduit . 32 7.1<	Variable	Label	Value	N	%	<= 20
PRCBRHYT f26q80: Antiarrhythmic agent pre CABG 1 17 3.8 * PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 * PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 * PRCBIVNI f26q8P: Fish oil pre CABG 1 160 35.6 2 281 62.6 PRCBIVNI f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 10 2.2 * PRCBIABP f26q9A: LAD grafted 1 46 10.2 307 LADCABGC f26q9A: LAD conduit . 32 7.1 4 B 302 67.3 . 1 10 2.2 LADCABGC f26q9A: LAD conduit . 32 7.1 4 89 19.8 B 302 67.3 . . 32 6.1 <td>PRCBINOT</td> <td>f26q8N: Inotropic agent pre CABG</td> <td>1</td> <td>6</td> <td>1.3</td> <td>*</td>	PRCBINOT	f26q8N: Inotropic agent pre CABG	1	6	1.3	*
PRCBRHYT f26q80: Antiarrhythmic agent pre CABG 1 17 3.8 426 94.9 3 6 1.3 * PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 3 6 1.3 * PRCBIVNI f26q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 281 62.6 3 8 1.8 * PRCBIVNI f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 426 94.9 * PRCBIABP f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 426 94.9 * PRCBIABP f26q8S: IABP pre CABG 1 10 2.2 * * * LADCABG f26q9A: LAD grafted 1 46 10.2 * * * LADCABGC f26q9A: LAD conduit . 32 7.1 * * * LADCABGC f26q9A: LAD conduit . 32 7.1 * * * LADCABGC f26q9A: LAD conduit . 32 7.1 *			2	437	97.3	
PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 3 6 1.3 * PRCBIVNI f26q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 281 62.6 3 8 1.8 PRCBIVNI f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * LADCABG f26q9A: LAD grafted 1 418 93.1 * LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 8 302 67.3 2 5.6 40.3 40.3 10.2 5.6 40.3 40.3 10.2 5.6 10.2 10.3 10.3 10.3 10.3 10.3 10.3 10.3 10.3			3	6	1.3	*
PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 3 6 1.3 * PRCBIVNI f26q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 281 62.6 3 8 1.8 PRCBIVNI f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * LADCABG f26q9A: LAD grafted 1 418 93.1 * LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 8 302 67.3 2 5.6 40.3 40.3 10.2 5.6 40.3 40.3 10.2 5.6 10.2 10.3 10.3 10.3 10.3 10.3 10.3 10.3 10.3						
PRCBFISH f26q8P: Fish oil pre CABG 2 443 98.7 PRCBIVNI f26q8Q: IV nitroglycerin pre CABG 1 160 35.6 PRCBIVNI f26q8Q: IV nitroglycerin pre CABG 1 160 35.6 PRCBIVNI f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * IADCABG f26q9A: LAD grafted 1 46 10.2 * IADCABGC f26q9A: LAD conduit . 32 67 1.3 IADCABGC f26q9A: LAD conduit . 32 7.1 A B 302 67.3 19.8 19.8 19.8 B 302 67.3 5.6 5.6 5.6	PRCBRHYT	f26q8O: Antiarrhythmic agent pre CABG	1	17	3.8	*
PRCBFISH 126q8P: Fish oil pre CABG 2 443 98.7 1.3 PRCBIVNI 126q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 2 281 62.6 2 281 62.6 3 8 1.8 PRCBTHRM 126q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBTARP 126q8S: IABP pre CABG 1 46 10.2 * PRCBIABP 126q8S: IABP pre CABG 1 46 10.2 * IADCABG 126q9A: LAD grafted 1 418 93.1 * LADCABGC 126q9A: LAD conduit . 32 7.1 * B 302 67.3 19.8 19.8 19.8 19.8 B 302 67.3 19.8 19.8 19.8 19.8 19.8			2	426	94.9	
PRCBIVNI 126q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 281 62.6 3 8 1.8 PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 Que de			3	6	1.3	*
PRCBIVNI 126q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 281 62.6 3 8 1.8 PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 Que de						
PRCBIVNI 126q8Q: IV nitroglycerin pre CABG 1 160 35.6 2 281 62.6 3 8 1.8 PRCBTHRM 126q8R: Thrombolytic therapy pre CABG 1 10 2.2 PRCBIABP 126q8S: IABP pre CABG 1 46 10.2 PRCBIABP 126q8S: IABP pre CABG 1 46 10.2 LADCABG 126q9A: LAD grafted 1 418 93.1 LADCABGC 126q9A: LAD conduit . 32 7.1 A 89 19.8 19.8 19.8 B 302 67.3 19.8 10.2 LADCABGC 126q9A: LAD conduit . 32 7.1 A 89 19.8 19.8 19.8 B 302 67.3 19.8 19.8 B 302 67.3 10.2 10.8 C 25 5.6 10.2 10.2	PRCBFISH	f26q8P: Fish oil pre CABG	2	443	98.7	
PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * LADCABG f26q9A: LAD grafted 1 418 93.1 * LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 . . 25 5.6 .			3	6	1.3	*
PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * LADCABG f26q9A: LAD grafted 1 418 93.1 * LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 . . 25 5.6 .						
PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 * LADCABG f26q9A: LAD grafted 1 418 93.1 * LADCABGC f26q9A: LAD conduit . 32 7.1 * LADCABGC f26q9A: LAD conduit . 32 7.1 * B 302 67.3 19.8 * *	PRCBIVNI	f26q8Q: IV nitroglycerin pre CABG	1	160	35.6	
PRCBTHRM f26q8R: Thrombolytic therapy pre CABG 1 10 2.2 * 2 426 94.9 3 13 2.9 * PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 2 397 88.4 3 6 1.3 * LADCABG f26q9A: LAD grafted 1 418 93.1 2 31 6.9 * LADCABGC f26q9A: LAD conduit . 32 7.1 48 9.1 1.3 6.9 * LADCABGC f26q9A: LAD conduit . 32 7.1 5.6 5.6 5.6			2	281	62.6	
PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 2 397 88.4 3 6 1.3 * LADCABG f26q9A: LAD grafted 1 418 93.1 LADCABGC f26q9A: LAD conduit . 32 7.1 B 302 67.3 C 25 5.6			3	8	1.8	*
PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 2 397 88.4 3 6 1.3 * LADCABG f26q9A: LAD grafted 1 418 93.1 LADCABGC f26q9A: LAD conduit . 32 7.1 B 302 67.3 C 25 5.6						
PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 2 397 88.4 3 6 1.3 * LADCABG f26q9A: LAD grafted 1 418 93.1 2 31 6.9 LADCABGC f26q9A: LAD conduit . 32 7.1 489 19.8 LADCABGC f26q9A: LAD conduit . 302 67.3 67.3 C 25 5.6 5.6 5.6 5.6	PRCBTHRM	f26q8R: Thrombolytic therapy pre CABG	1	10	2.2	*
PRCBIABP f26q8S: IABP pre CABG 1 46 10.2 2 397 88.4 3 6 1.3 * LADCABG f26q9A: LAD grafted 1 418 93.1 LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6			2	426	94.9	
2 397 88.4 3 6 1.3 LADCABG f26q9A: LAD grafted 1 418 93.1 2 31 6.9 LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6			3	13	2.9	*
2 397 88.4 3 6 1.3 LADCABG f26q9A: LAD grafted 1 418 93.1 2 31 6.9 LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6						
3 6 1.3 * LADCABG f26q9A: LAD grafted 1 418 93.1 2 31 6.9 LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6	PRCBIABP	f26q8S: IABP pre CABG	1	46	10.2	
LADCABG f26q9A: LAD grafted 1 418 93.1 2 31 6.9 LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6			2	397	88.4	
LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6			3	6	1.3	*
LADCABGC f26q9A: LAD conduit . 32 7.1 A 89 19.8 B 302 67.3 C 25 5.6						
LADCABGC f26q9A: LAD conduit A 89 19.8 B 302 67.3 C 25 5.6	LADCABG	f26q9A: LAD grafted	1	418	93.1	
A 89 19.8 B 302 67.3 C 25 5.6			2	31	6.9	
A 89 19.8 B 302 67.3 C 25 5.6						
B30267.3C255.6	LADCABGC	f26q9A: LAD conduit		32	7.1	
C 25 5.6			А	89	19.8	
			В	302	67.3	
D 1 0.2 *			С	25	5.6	
			D	1	0.2	*

T3B form26

Variable	Label	Value	N	%	<= 20
D1CABG	f26q9B: 1st diagonal grafted		1	0.2	*
		1	132	29.4	
		2	316	70.4	
D1CABGC	f26q9B: 1st diagonal conduit		318	70.8	
		А	99	22.0	
		В	28	6.2	
		С	2	0.4	*
		D	2	0.4	*
D2CABG	f26q9C: 2nd diagonal grafted		1	0.2	*
		1	32	7.1	
		2	416	92.7	
D2CABGC	f26q9C: 2nd diagonal conduit		417	92.9	
		А	24	5.3	
		В	8	1.8	*
CFCABG	f26q9D: Circumflex grafted		2	0.4	*
		1	72	16.0	
		2	375	83.5	
CFCABGC	f26q9D: Circumflex conduit		377	84.0	
		А	64	14.3	
		В	5	1.1	*
		С	3	0.7	*
OM1CABG	f26q9E: 1st obtuse marginal grafted	•	1	0.2	*
		1	198	44.1	
		2	250	55.7	

T3B form26

Variable	Label	Value	N	%	<= 20
OM1CABGC	f26q9E: 1st obtuse marginal conduit		251	55.9	
		А	174	38.8	
		В	16	3.6	*
		С	8	1.8	*
OM2CABG	f26q9F: 2nd obtuse marginal grafted		2	0.4	*
		1	110	24.5	
		2	337	75.1	
OM2CABGC	f26q9F: 2nd obtuse marginal conduit		339	75.5	
		А	96	21.4	
		В	10	2.2	*
		С	4	0.9	*
OM3CABG	f26q9G: 3rd obtuse marginal grafted		2	0.4	*
		1	24	5.3	
		2	423	94.2	
OM3CABGC	f26q9G: 3rd obtuse marginal conduit		425	94.7	
		А	19	4.2	*
		В	4	0.9	*
		С	1	0.2	*
RICABG	f26q9H: Ramus intermedius grafted		2	0.4	*
		1	28	6.2	
		2	419	93.3	
RICABGC	f26q9H: Ramus intermedius conduit		421	93.8	
		А	25	5.6	
		В	2	0.4	*
		С	1	0.2	*

T3B form26

Variable	Label	Value	Ν	%	<= 20
RCACABG	f26q9I: RCA grafted		2	0.4	*
		1	194	43.2	
		2	253	56.3	
RCACABGC	f26q9I: RCA conduit		255	56.8	
		А	181	40.3	
		В	3	0.7	*
		С	10	2.2	*
PDACABG	f26q9J: PDA grafted		2	0.4	*
		1	154	34.3	
		2	293	65.3	
PDACABGC	f26q9J: PDA conduit		295	65.7	
		А	139	31.0	
		В	4	0.9	*
		С	7	1.6	*
		D	4	0.9	*
REVSCABG	f26q10: Revascularization complete	1	374	83.3	
		2	65	14.5	
		3	10	2.2	*
CABGTUBE	f26q10O: Chest tube not removed > 5 days		439	97.8	
		1	10	2.2	*
CABGEVNT	f26q11: Any major events	1	78	17.4	
		2	371	82.6	

T3B form26

Variable	Label	Value	N	%	<= 20
DTH24	f26q11A: Death within 24 hrs		381	84.9	
		1	61	13.6	
		2	3	0.7	*
		3	4	0.9	*
CABGCA	f26q11B: Non-fatal cardiac arrest		371	82.6	
		1	72	16.0	
		2	4	0.9	*
		3	2	0.4	*
CABGMI	f26q11C: Suspected MI		371	82.6	
		1	48	10.7	
		2	19	4.2	*
		3	11	2.4	*
CABGCHF	f26q11D: Congestive heart failure		371	82.6	
		1	69	15.4	
		2	1	0.2	*
		3	8	1.8	*
CABGEDEM	f26q11E: Pulmonary edema		371	82.6	
		1	71	15.8	
		2	2	0.4	*
		3	5	1.1	*
CABGSHCK	f26q11F: Cardiogenic shock		371	82.6	
		1	64	14.3	
		2	5	1.1	*
		3	9	2.0	*

T3B form26

Variable	Label	Value	N	%	<= 20
CABGTAMP	f26q11G: Cardiac tamponade	•	371	82.6	
		1	73	16.3	
		3	5	1.1	*
CABGEMBO	f26q11H: Arterial embolus		371	82.6	
		1	74	16.5	
		2	2	0.4	*
		3	2	0.4	*
CABGDISS	f26q11I: Arterial dissection		371	82.6	
		1	75	16.7	
		2	2	0.4	*
		3	1	0.2	*
CABGTIA	f26q11J: TIA		371	82.6	
		1	78	17.4	
CABGSTRK	f26q11K: Stroke		371	82.6	
		1	73	16.3	
		2	2	0.4	*
		3	3	0.7	*
CABGCOMA	f26q11L: Coma		371	82.6	
		1	76	16.9	
		2	1	0.2	*
		3	1	0.2	*
CABGALRG	f26q11M: Hypersensitivity		371	82.6	
		1	78	17.4	

T3B form26

Variable	Label	Value	Ν	%	<= 20
CABGARDS	f26q11N: Respiratory failure		371	82.6	
		1	72	16.0	
		2	2	0.4	*
		3	4	0.9	*
CABGPLEM	f26q11O: Pulmonary embolus		371	82.6	
		1	78	17.4	
CABGDIAL	f26q11P: Renal failure		371	82.6	
		1	78	17.4	
CABGREOP	f26q11Q: Re-operation for bleeding		371	82.6	
		1	66	14.7	
		2	1	0.2	*
		3	11	2.4	*
CABGWND	f26q11R: Wound dehiscence		371	82.6	
		1	78	17.4	
CABGINF	f26q11S: Mediastinitis		371	82.6	
		1	78	17.4	
CABGOTEV	f26q11T: Other events		371	82.6	
		1	66	14.7	
		2	2	0.4	*
		3	10	2.2	*
CABGSTAT	f26q12: Condition leaving O.R.	1	426	94.9	
		2	20	4.5	*
		3	3	0.7	*

T3B form26

Variable	Label	Ν	Mean	Std Dev	Minimum	Maximum
FM26DAY	f26q2: Days to surgery	448	57.3	118.5	1.0	804.0